Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical
Evotec AG announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and initiated a new discovery collaboration. Under the contract extension Evotec will provide integrated drug discovery activities, including high throughput screening, medicinal chemistry and in vitro pharmacology to discover novel, small molecular weight compounds active against an ion channel target selected by Ono. Ono will access Evotec’s ion channel drug discovery platform and expertise and Evotec will receive research funding and milestone payments.
Evotec and Ono have collaborated since March 2008 identifying novel inhibitors for a protease target. Within this collaboration Evotec provides protein crystallography, medicinal chemistry, biology and ADMET services to Ono with the aim of progressing a compound towards clinical development.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Revolutionary new insights into blood vessel formation in cancer - Research opens new avenue for cancer therapy
Antisense Pharma Obtains IND for Clinical Studies in the USA - The American Department of Health, the FDA, agrees to the use of trabedersen for high-grade glioma (malignant brain tumor)

Novel antibiotics in the fight against antimicrobial resistance - SANTERO announces a €8 million Series A funding round led by Newton Biocapital
KÖTTERMANN finds an investor

Combination Therapy against Cancer - Synergistic anticancer therapy with two cell killer agent systems in one nanocapsule

QUANTRO Therapeutics receives important Austrian research funding to further develop its platform for the discovery of novel cancer therapies - Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform
Max-Planck-Institut für Entwicklungsbiologie - Tübingen, Germany

Cell Cultivated Leather - VitroLabs raises $46 million to build and scale the world's first pilot production of cell cultivated leather
Summit's lead drug candidate enters phase II clinical trials - Candidate targets sialorrhoea, a symptom of Parkinson's disease
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt, an FDA-approved oral therapy for schizophrenia
